Medconn Diagnostics Showcases Flagship Products at ADLM 2025 in Chicago
2025-08-07Chicago, US — July 2025 Medconn Diagnostics successfully participated in ADLM 2025, one of the most prestigious global events held this year in Chicago. Attracting a high volume of visitors, Medconn booth highlighted the company’s expanding portfolio and commitment to innovative, high-performance diagnostic solutions.
A focal point of Medconn’s exhibition was the HPLC HbA1c Analyzer, MQ series, presented in four distinct models. Among them, the MQ-3000 garnered significant attention, having received FDA 510(k) clearance this year. Utilizing the gold standard HPLC method, the MQ-3000 delivers accurate and reliable results for HbA1c testing, common hemoglobin variant detection (C, D, E, S), and thalassemia screening (HbA2, HbF).
In addition to its HPLC lineup, Medconn showcased two models from its hematology analyzer series — MH-60 and DX-80. Both are five-part differential analyzers and featured with pRBC detection for malaria and immature granulocyte (IG) reporting.
Beyond hardware, Medconn emphasized its commitment to delivering comprehensive clinical laboratory solutions. Visitors were introduced to the company’s integrated AI diagnostic software and Laboratory Information System (LIS).
From advanced instrumentation to intelligent software and dedicated service, Medconn is shaping the future of clinical diagnostics with precision and reliability.
